Holen Sie sich die Stockscreener-App
5.89
2.81%
0.19
Schlusskurs vom Vortag:
$5.70
Offen:
$5.73
24-Stunden-Volumen:
465.64K
Relative Volume:
0.70
Marktkapitalisierung:
$275.89M
Einnahmen:
$15.84M
Nettoeinkommen (Verlust:
$-308.48M
KGV:
-1.4949
EPS:
-3.94
Netto-Cashflow:
$-153.08M
1W Leistung:
-13.19%
1M Leistung:
-11.21%
6M Leistung:
+22.08%
1J Leistung:
-12.93%
1-Tages-Spanne:
$5.5101
$5.92
1-Wochen-Bereich:
$5.50
$6.83
52-Wochen-Spanne:
$3.73
$11.35
Uniqure N V Stock (QURE) Company Profile
Firmenname
Uniqure N V
Sektor
Branche
Telefon
1-339-970-7000
Adresse
PAASHEUVELWEG 25A, AMSTERDAM
Vergleichen Sie QURE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| QURE | 5.89 | 275.89M | 15.84M | -308.48M | -153.08M | -3.94 |
| VRTX | 449.14 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.83 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 587.39 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.01 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.99 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-03-17 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-01 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-11-11 | Eingeleitet | Berenberg | Buy |
| 2020-11-09 | Eingeleitet | Jefferies | Buy |
| 2020-11-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-08-25 | Eingeleitet | Raymond James | Strong Buy |
| 2020-07-31 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-06-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Eingeleitet | Cowen | Outperform |
| 2019-12-03 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Eingeleitet | Credit Suisse | Outperform |
| 2019-10-11 | Eingeleitet | Stifel | Buy |
| 2019-09-25 | Eingeleitet | Bernstein | Outperform |
| 2019-09-12 | Eingeleitet | Mizuho | Buy |
| 2019-07-30 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-07-08 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Uniqure N V Aktie (QURE) Neueste Nachrichten
uniQure Begins Phase I/IIa Trial for AMT-260 Therapy - TipRanks
uniQure announces first patient dosed in GenTLE Phase I/IIa trial of AMT-260 - TipRanks
uniQure Announces Dosing of First Patient in GenTLE Phase - GlobeNewswire
uniQure Launches Phase I/IIa Gene Therapy Trial for Drug-Resistant Epilepsy Treatment | QURE Stock News - StockTitan
uniQure (NASDAQ:QURE) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
(QURE) Investment Analysis - Stock Traders Daily
uniQure NV (LTS:0EE0) Enterprise Value : $-65.19 Mil (As of Nov. 16, 2024) - GuruFocus.com
uniQure FY2024 EPS Estimate Reduced by Cantor Fitzgerald - MarketBeat
Privium Fund Management B.V. Acquires 104,500 Shares of uniQure (NASDAQ:QURE) - MarketBeat
Wall Street Analysts Believe uniQure (QURE) Could Rally 169.18%: Here's is How to Trade - Yahoo Finance
(QURE) On The My Stocks Page - Stock Traders Daily
uniQure FY2024 EPS Estimate Boosted by Leerink Partnrs - MarketBeat
HC Wainwright Issues Positive Estimate for uniQure Earnings - MarketBeat
William Blair Issues Positive Estimate for uniQure Earnings - MarketBeat
Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market EvolutionTechnavio - cnhinews.com
What Does The Future Hold For uniQure N.V. (NASDAQ:QURE)? These Analysts Have Been Cutting Their Estimates - Yahoo Finance
QUREuniQure N.V. Latest Stock News & Market Updates - StockTitan
Cantor Fitzgerald Reaffirms "Overweight" Rating for uniQure (NASDAQ:QURE) - MarketBeat
uniQure Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
uniQure N.V. Reports Q3 2024 Progress and Financials - TipRanks
uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress - GlobeNewswire
Uniqure NV earnings beat by $0.11, revenue fell short of estimates - Investing.com Australia
UniQure: Q3 Earnings Snapshot - San Francisco Chronicle
uniQure NV Q3 2024 Earnings: EPS Loss of $0.91 Beats Estimates, Revenue of $2.3 Million Misses Expectations - GuruFocus.com
uniQure reports Q3 EPS (91c), consensus ($1.01) - TipRanks
UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
uniQure's Breakthrough: Huntington's Trial Success, $435M Cash Runway Through 2027 | QURE Stock News - StockTitan
abrdn plc Buys 1,528,581 Shares of uniQure (NASDAQ:QURE) - MarketBeat
Assenagon Asset Management S.A. Has $1.34 Million Stake in uniQure (NASDAQ:QURE) - MarketBeat
Multiple Insiders Sold uniQure Shares Presenting Weak Signs For Investors - Simply Wall St
UniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Yahoo Finance
uniQure (NASDAQ:QURE) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Pfizer Loses Hemophilia Gene Therapy Patent Row To UniQure - Law360
uniQure’s Yellow Flags: Early-Stage Gene Therapies Amid Restructuring - Seeking Alpha
State Street Corp's Strategic Reduction in uniQure NV Holdings - GuruFocus.com
How To Trade (QURE) - Stock Traders Daily
uniQure (NASDAQ:QURE) Upgraded to Sell by StockNews.com - MarketBeat
uniQure (NASDAQ:QURE) Upgraded by StockNews.com to “Sell” - Defense World
uniQure N.V. (QURE) requires closer examination - US Post News
uniQure Initiates Trial for Promising ALS Gene Therapy - TipRanks
uniQure announces dosing of first patient in Phase I/II trial of AMT-162 - TipRanks
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment of SOD1-ALS - GlobeNewswire
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS - StockTitan
Raymond James gives an Outperform recommendation for uniQure N.V. (QURE) - Knox Daily
Ratios Uncovered: Breaking Down uniQure N.V. (QURE)’s Trailing Twelve Months Metrics - The Dwinnex
Marshall Wace LLP Invests $175,000 in uniQure (NASDAQ:QURE) - Defense World
uniQure shares coverage resumed on robust clinical portfolio - Investing.com
Raymond James Reiterates Outperform Rating for uniQure (NASDAQ:QURE) - MarketBeat
uniQure shares coverage resumed on robust clinical portfolio By Investing.com - Investing.com UK
A company insider recently sold 1,447 shares of uniQure N.V. [QURE]. Should You Sale? - Knox Daily
An analyst sees good growth prospects for uniQure N.V. (QURE) - SETE News
Finanzdaten der Uniqure N V-Aktie (QURE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Uniqure N V-Aktie (QURE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| CALOZ PIERRE | Chief Operating Officer |
Jun 17 '24 |
Sale |
4.81 |
2,936 |
14,122 |
115,707 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Jun 17 '24 |
Sale |
4.80 |
1,611 |
7,733 |
164,837 |
| POST LEONARD E | Director |
Jun 13 '24 |
Sale |
5.14 |
2,222 |
11,421 |
15,999 |
| Potts Jeannette | Chief Legal Officer |
Jun 13 '24 |
Sale |
4.98 |
4,781 |
23,809 |
91,819 |
| Springhorn Jeremy P. | Director |
Jun 13 '24 |
Sale |
5.12 |
2,231 |
11,423 |
23,756 |
| Meek David D. | Director |
Jun 13 '24 |
Sale |
5.12 |
2,229 |
11,412 |
20,252 |
| Balachandran Madhavan | Director |
Jun 13 '24 |
Sale |
5.12 |
2,231 |
11,423 |
23,759 |
| Soteropoulos Paula | Director |
Jun 13 '24 |
Sale |
5.14 |
2,220 |
11,411 |
20,203 |
| Gut Robert | Director |
Jun 13 '24 |
Sale |
5.12 |
3,504 |
17,940 |
44,165 |
| Kaye Jack | Director |
Jun 13 '24 |
Sale |
5.16 |
2,218 |
11,445 |
6,501 |
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):